Skip to content

Author

M. Hossan

We have 6 of 63 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B021: Epigenetic Reprogramming of Intraductal Papillary Mucinous Neoplasms (IPMNs) by Pancreatic Cancer Associated Fibroblasts

Intraductal papillary mucinous neoplasms (IPMNs) are established precursors to pancreatic ductal adenocarcinoma (PDAC). While IPMNs are the only pancreatic precursor readily identified by clinical imaging, no tools readily predict progression to cancer. The local pancreatic tumor microenvironment (TME) is heavily...

Hailee I. Porter, M. S. Hossan, Timothy Hoggard et al. · 0 citations
Sep 2026

Abstract A036: Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with an unmet need for novel precision based therapies. While KRAS canonically drives tumor progression, MYC amplification has emerged as a critical downstream resistance mechanism. Efforts have been made to elucidate the role of MYC amplification in PDAC...

Audrey G. Sawyer, Lauryn E. Flannagan, Paulina N. Esguerra et al. · 0 citations
Sep 2026

Abstract B127: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma

It is demonstrated that dual BET and CDK9 inhibition promotes transcriptional pausing and suppresses key regulators in transcriptionally driven cancers, as well as demonstrating on-target transcriptional inhibition.

Paulina N. Esguerra, Michela Cadarso, Sasha Livingwell et al. · 0 citations
Sep 2026

Abstract B043: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma

A patient-derived cancer organoid (PCO) model that is MYC-amplified is examined to assess the activity of combining CDK9 inhibition (SLS009) with tricomplex RAS (ON inhibitors) studying both RMC-6236 and RMC-9805 and significantly augments the induction of apoptosis and necrosis compared to single agent activity.

Michela Cadarso, Paulina N. Esguerra, Lauryn E. Flannagan et al. · 0 citations
#protein folding Sep 2026

Abstract B052: Understanding latent resistance mechanisms and their phenotypes in pancreatic cancer organoids under KRASG12D inhibition

The rate of acquired resistance to Zoldonrasib was found to be rapid in PCO models and independent of EGF stimulation, and opposing signaling pathway activation in resistant PCOs to Zoldonrasib at 200nM dependent upon EGF stimulation was suggested.

Lauryn E. Flannagan, Michela Cadarso, Audrey G. Sawyer et al. · 0 citations
Open access Jul 2026

Long-read, whole-genome sequencing and chemotherapy response of two patient-derived organoids from a TP53- and KRAS-mutant ovarian carcinoma

Two PDOs with differential responses to carboplatin derived from sequential ascites fluid collections from a patient with high-grade müllerian carcinoma are described and the ability of long-read sequencing to add detail into the genomics and epigenetics of ovarian cancer is demonstrated.

J. Wendt, Kristin M. Adams, Ryan Moreno et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.